Your tendons are more than passive cables transmitting force from muscle to bone. They're dynamic, living tissues that constantly sense mechanical stress and adapt their internal structure. At the heart of this adaptation is tenascin C¹¹ tenascin C
a large hexameric glycoprotein that acts as a molecular shock absorber, expressed at myotendinous junctions and upregulated during tissue repair and mechanical loading. The TNC gene encodes this protein, and the rs2104772 variant determines how well your tendons can withstand the repetitive high-force contractions that define elite athletic performance.

The rs2104772 polymorphism sits in exon 17 of the TNC gene, within a fibronectin type III domain²² fibronectin type III domain
one of multiple modular protein domains that give tenascin C its characteristic elasticity. This single-nucleotide change swaps isoleucine for leucine at position 1677 of the protein. While both are hydrophobic amino acids, this substitution affects protein folding and function. Studies show the T variant associates with lower tenascin C protein content³³ Studies show the T variant associates with lower tenascin C protein content
Butt et al. found reduced TNC expression in T/T carriers, which impairs molecular elasticity and compromises the extracellular matrix's ability to buffer mechanical stress.

The Mechanism

Tenascin C is a mechano-regulated protein. When you load a tendon—sprinting, jumping, cutting—mechanical stress activates the Rho/ROCK signaling cascade⁴⁴ Rho/ROCK signaling cascade
a molecular pathway that translates physical force into chemical signals, upregulating TNC gene expression. The resulting tenascin C molecules assemble into hexameric structures that can stretch to several times their resting length, protecting collagen fibers from damage during high-strain events.

The rs2104772 variant disrupts this protective system. The T-to-A substitution (creating the Ile1677Leu change) sits in a functionally critical region. Carriers of the T allele produce less tenascin C protein overall, and what they do produce has reduced elasticity. This means less cushioning for the collagen scaffold during eccentric loading—the phase of muscle contraction when tendons experience peak tensile stress, like when your hamstring decelerates your leg during the late swing phase of sprinting, or when your Achilles absorbs impact during the push-off phase of running.

The functional consequences extend beyond tendon mechanics. Tenascin C regulates cell-matrix interactions and plays a central role in the muscle damage-repair cycle. A Swiss endurance training study⁵⁵ A Swiss endurance training study
Valdivieso et al., PLOS One 2017 found that T/T individuals showed a 15% decrease in capillary-to-fiber ratio after six weeks of cycling training, while A-allele carriers increased capillary density as expected. The T/T genotype was also associated with 3.1-fold reduced vimentin protein after training—a marker of impaired vascular remodeling. This suggests the variant affects not just tendon structure but the broader tissue adaptation response to mechanical loading.

The Evidence

The association between rs2104772 and tendon injury is well-replicated across multiple athletic populations and injury types:

Achilles tendinopathy: A case-control study of Croatian elite athletes⁶⁶ A case-control study of Croatian elite athletes
Jerić et al., Genes 2025 genotyped 63 tendinopathy cases and 92 controls. The T/T genotype was significantly overrepresented in cases (42.9% vs 22.8%, p=0.0089), with an odds ratio of 2.54 (95% CI: 1.26–5.09). Each copy of the T allele increased risk by 68% (OR=1.68, 95% CI: 1.06–2.66), while the A allele was protective (OR=0.60).

Hamstring injury in soccer: A prospective study of 107 elite male soccer players⁷⁷ A prospective study of 107 elite male soccer players
Larruskain et al., Med Sci Sports Exerc 2018 tracked 129 hamstring injuries over six seasons. In a multivariable Cox model, each T allele increased hamstring injury hazard by 65% (HR=1.65, 95% CI: 1.17–2.32). The genetic model showed acceptable discrimination in the discovery phase (C-index=0.74) but failed to validate prospectively (C-index=0.52), suggesting genetic variants contribute to etiology but lack standalone predictive value.

ACL rupture (sex-specific): Whole-exome sequencing of Achilles and ACL cases⁸⁸ Whole-exome sequencing of Achilles and ACL cases
Ficek et al., PLOS One 2018 found the A/A genotype significantly associated with ACL ruptures in female athletes (p=0.035, OR=2.3, 95% CI: 1.1–5.5), though this finding was not replicated in Polish Caucasian participants, suggesting population-specific effects.

Exercise-induced angiogenesis: A Swiss training study⁹⁹ A Swiss training study
Valdivieso et al., PLOS One 2017 enrolled 61 untrained males for six weeks of endurance cycling. T/T homozygotes (18% of the cohort) showed impaired capillary remodeling: training decreased their capillary-to-fiber ratio by 15%, while A-allele carriers increased it as expected. The T/T genotype also blunted vimentin upregulation, a marker of vascular adaptation.

The mechanism is biologically plausible. Tenascin C is expressed in regenerating myofibers and at the myotendinous junction—the most vulnerable site for hamstring and Achilles injuries. It provides strength and elasticity to withstand mechanical forces and regulates the tissue's response to mechanical loading. Lower TNC expression reduces the extracellular matrix's shock-absorbing capacity, increasing strain on collagen fibers during high-force eccentric contractions.

Practical Actions

If you carry the T allele—especially if you're T/T—your tendons have reduced built-in protection against mechanical stress. This doesn't mean you're destined for injury, but it does mean you need to be strategic about load management, tissue quality, and recovery.

Progressive loading is non-negotiable. Tendon adaptation is slow—much slower than muscle adaptation. A muscle can gain strength in 4-6 weeks; a tendon needs 12-16 weeks to meaningfully increase stiffness and collagen cross-linking. Eccentric and heavy slow resistance protocols both work¹⁰¹⁰ Eccentric and heavy slow resistance protocols both work, but the key is gradual progression. Increase volume or intensity by no more than 10% per week. Avoid sudden spikes in training load—these are the scenarios where your reduced tenascin C expression leaves collagen fibers vulnerable.

Collagen peptide supplementation has emerging evidence. 15 grams of hydrolyzed collagen¹¹¹¹ 15 grams of hydrolyzed collagen
containing glycine, proline, and hydroxyproline taken 60 minutes before exercise increases circulating amino acids (glycine up 376 mmol/L, proline up 162 mmol/L) and provides the building blocks for collagen synthesis. A study in female soccer players¹²¹² A study in female soccer players
Shaw et al., Front Physiol 2023 found collagen supplementation augmented patellar tendon stiffness changes during training. Take it with 50 mg vitamin C—vitamin C acts as a cofactor¹³¹³ vitamin C acts as a cofactor
hydroxylating proline and lysine residues in the collagen synthesis pathway.

Monitor for early warning signs. Tendinopathy typically progresses through stages: reactive tendinopathy (acute overload), tendon dysrepair (failed healing), and degenerative tendinopathy (irreversible structural changes). Catch it early. If you notice morning stiffness that warms up, localized tenderness along the Achilles or hamstring tendon, or pain during loading that eases with rest, reduce training volume immediately and consult a sports physiotherapist. Progressive tendon-loading exercises¹⁴¹⁴ Progressive tendon-loading exercises are more effective than rest alone, but they need to be dosed correctly.

Prioritize recovery between high-eccentric sessions. Eccentric exercise—downhill running, plyometrics, Nordic hamstring curls, heavy negatives—causes greater muscle and tendon damage than concentric work, especially in T/T individuals. The Swiss angiogenesis study¹⁵¹⁵ Swiss angiogenesis study showed T/T carriers had impaired vascular remodeling, meaning slower nutrient delivery and waste removal. Allow 48-72 hours between high-eccentric sessions. Use isometric holds (e.g., Spanish squats for Achilles, isometric hamstring bridges) on recovery days—these build tendon tolerance without excessive strain.

Interactions

TNC rs2104772 doesn't act in isolation. The Croatian study identified a T-T-T haplotype¹⁶¹⁶ The Croatian study identified a T-T-T haplotype combining TNC rs2104772-T, COL27A1 rs946053-T, and COL5A1 rs12722-T that was significantly predisposing for tendinopathy, while the G-A-C haplotype was protective. The biological logic is clear: COL5A1 encodes type V collagen, which regulates collagen fibril assembly and diameter, while COL27A1 contributes to cartilage and tendon structure. If you carry risk alleles in multiple collagen-pathway genes, the combined effect on extracellular matrix integrity is greater than any single variant.

There's also evidence for interaction with MMP3 rs679620¹⁷¹⁷ interaction with MMP3 rs679620. MMP3 encodes matrix metalloproteinase-3, an enzyme that degrades extracellular matrix proteins during tissue remodeling. The G allele of MMP3 rs679620 and the T allele of TNC rs2104772 significantly interacted to raise Achilles tendinopathy risk (p=0.006). This makes mechanistic sense: reduced tenascin C (from TNC T/T) combined with elevated MMP3 activity (from MMP3 G/G) creates a scenario where the extracellular matrix is simultaneously less resilient and more actively degraded.

Finally, consider the hamstring injury genetic model¹⁸¹⁸ hamstring injury genetic model that included TNC rs2104772 alongside MMP3 rs679620, IL-6 rs1800795, NOS3 rs1799983, and HIF-1α rs11549465. These genes regulate inflammation (IL-6), nitric oxide signaling (NOS3), and hypoxic adaptation (HIF-1α). The multivariable model had a C-index of 0.74 in the discovery cohort, suggesting genetic variants collectively explain a meaningful fraction of hamstring injury risk. While the model didn't validate prospectively for prediction, it underscores that tendon injury is a complex trait influenced by ECM structure, inflammation, vascular health, and metabolic stress response.

FABP1 (Fatty Acid Binding Protein 1), also called L-FABP or liver FABP, is the most abundant cytosolic protein in human hepatocytes. It binds long-chain fatty acids, bile acids, and other hydrophobic ligands and shuttles them from the plasma membrane to the endoplasmic reticulum and mitochondria for esterification and oxidation¹¹ FABP1 constitutes roughly 3-5% of total cytosolic protein in the adult human liver; its extraordinary abundance reflects the hepatocyte's central role in whole-body lipid homeostasis. By modulating the intracellular concentration of free fatty acids, FABP1 directly influences hepatic triglyceride synthesis, VLDL secretion, and fat oxidation.

rs2197076 is a G>A intronic variant in FABP1 (GRCh38: chr2:88,123,239; NM_001443.3:c.334-135C>T in coding-strand notation — the gene sits on the minus strand, so the plus-strand reference is G and the alternate is A). The variant does not alter the FABP1 protein sequence; its clinical relevance lies in its association with diabetes and metabolic risk phenotypes, and in its position within the same haplotype block as the T94A missense variant (rs2241883)²² T94A missense variant (rs2241883)
rs2241883 is a coding variant in FABP1 that substitutes alanine for threonine at position 94 of the protein; this structural change reduces the protein's fatty acid binding affinity and has been independently linked to elevated triglycerides, LDL, and NAFLD risk.

The Mechanism

As an intronic variant, rs2197076 does not directly alter FABP1 protein function. Its biological significance is likely one of two types: it may influence the transcriptional regulation of FABP1 — reducing hepatic FABP1 expression so that fewer binding sites are available for incoming fatty acids — or it may serve as a tag SNP³³ tag SNP
A tag SNP is in linkage disequilibrium with one or more functional variants in the same haplotype block; the tag SNP itself may be functionally neutral, but its presence reliably predicts the presence of the functional allele elsewhere on the chromosome marking the T94A haplotype.

The liver FABP1 protein binds two fatty acid molecules simultaneously — a unique feature among the FABP family — enabling high-flux lipid transport in hepatocytes that process a continuous dietary fat load. When FABP1 is reduced or its binding affinity is impaired, free long-chain fatty acids accumulate in the cytosol, activate nuclear receptors differently, and may increase hepatic lipid deposition, triglyceride synthesis, and insulin resistance signaling. The A allele of rs2197076 is the minor allele in African and European populations (~9–18%) but approaches or exceeds 50% in East and South Asian populations, making it a particularly relevant variant for those ancestries.

The Evidence

The primary evidence for rs2197076 comes from a Spanish population study by Mansego et al.⁴⁴ Spanish population study by Mansego et al.
Mansego ML et al. Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PLoS One 2012 that examined 1,217 participants in an original cohort and replicated findings in 805 Segovia subjects. rs2197076 was the only single SNP in FABP1 to reach strong association with type 2 diabetes risk in both cohorts, and FABP1 haplotypes containing this variant also associated with HOMA-IR (a direct index of insulin resistance). No FABP2, FABP3, or FABP4 variants showed similar associations in the same study.

Two studies in polycystic ovary syndrome provide convergent evidence. Xue et al. 2016⁵⁵ Xue et al. 2016
Xue H et al. Association of SNPs rs2197076 and rs2241883 of FABP1 gene with PCOS. J Assist Reprod Genet 2016 genotyped both rs2197076 and the T94A coding variant in 221 Chinese PCOS women and 198 controls, finding P<0.001 for allele frequency differences; rs2197076 associated more strongly with core PCOS features than rs2241883, suggesting an independent regulatory contribution. Rashid et al. 2017⁶⁶ Rashid et al. 2017
Rashid N et al. Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with metabolic features of PCOS. Inflamm Res 2017 confirmed that the A allele specifically correlated with dyslipidemia and cardiovascular risk biomarkers in PCOS patients.

Mechanistic context for the haplotype is provided by studies of the T94A coding variant (rs2241883). Schroeder et al. 2016⁷⁷ Schroeder et al. 2016
Schroeder F et al. Fatty acid binding protein-1 and the human FABP1 T94A variant: roles in the endocannabinoid system and dyslipidemias. Lipids 2016 reviewed evidence that T94A expression in males increases hepatic triglycerides and cholesteryl esters through disrupted endocannabinoid enzyme transcription. The T94A variant also shows sex-dependent effects — female carriers exhibit compensatory metabolic adjustments that limit lipid accumulation relative to males. Whether rs2197076 tracks these effects independently or entirely through LD with rs2241883 is not yet resolved, but the combined evidence positions the FABP1 locus as a genuine metabolic risk factor, particularly for individuals of East and South Asian ancestry where the A allele is common.

The overall evidence supports a moderate rating: findings are replicated across three independent studies but remain confined to relatively small cohorts and specific populations, with no large GWAS signal or clinical-grade guideline.

Practical Actions

For A-allele carriers, the key leverage points are dietary fat quality, hepatic biomarker monitoring, and awareness of insulin resistance risk. Since FABP1 handles the intracellular distribution of fatty acids in the liver, the composition of dietary fat matters: saturated and trans fats promote hepatic triglyceride accumulation, while long-chain omega-3 fatty acids (EPA/DHA) activate hepatic PPARα and reduce triglyceride synthesis. Monitoring fasting triglycerides and glucose provides an early window into whether FABP1 haplotype variation is expressing itself metabolically.

Interactions

rs2197076 is physically close to and likely in partial linkage disequilibrium with rs2241883 (T94A), the missense variant in FABP1 exon 3. Both SNPs have been studied together in PCOS cohorts. The T94A missense has independent literature supporting its effect on lipid metabolism and NAFLD. If you carry risk alleles at both rs2197076 and rs2241883, the combined FABP1 haplotype may represent greater impairment of hepatic fatty acid handling than either SNP alone, though no published study has formally quantified a compound effect.

The FABP1 locus also intersects with dietary fat intake: the variant's metabolic effects are more pronounced in high-fat dietary contexts where hepatic FABP1 is under greatest demand. Individuals with FABP family risk variants (including FABP2 Ala54Thr, rs1799883) may carry compound metabolic fatty acid handling burden across intestinal absorption and hepatic transport.

The mTOR (mechanistic target of rapamycin) protein is the central command node for one of the most consequential decisions cells make: whether to grow or to clean house. When nutrients and growth signals are abundant, mTOR drives protein synthesis and cell proliferation. When mTOR is suppressed — by fasting, caloric restriction, or rapamycin — cells shift toward autophagy and stress resistance, the cellular programs most closely tied to longevity across every organism where this has been tested. rs2536 is a variant in the 3' untranslated region (3'UTR) of the MTOR gene that adjusts this setting through a post-transcriptional mechanism distinct from the promoter variant rs2295080.

The two MTOR variants in the GeneOps database regulate mTOR expression through different molecular mechanisms but converge on the same biology: lower mTOR activity means more autophagy, better protein quality control, and — based on the cancer and survival data — measurably better outcomes in contexts where mTOR overactivity drives disease.

The Mechanism

rs2536 sits in the 3' untranslated region of the MTOR gene — the portion of the mRNA that comes after the stop codon and is never translated into protein. The 3'UTR is not silent: it is the primary docking site for microRNAs (miRNAs), short RNA molecules that bind to the 3'UTR and suppress gene expression by either blocking translation or triggering mRNA degradation.

The rs2536 T>C substitution alters a binding site for microRNA-150 (miR-150)¹¹ microRNA-150 (miR-150)
a miRNA expressed broadly in immune, vascular, and epithelial tissues that normally suppresses several growth-promoting genes. The C allele creates a higher-affinity miR-150 binding site compared to the T allele. When miR-150 binds more strongly, it more efficiently suppresses MTOR mRNA translation — meaning C-allele carriers have lower MTOR protein levels in their tissues.

Direct expression analysis confirmed this²² Direct expression analysis confirmed this
Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. Int J Cancer, 2019: in 144 patients' adjacent normal gastric tissue samples, MTOR mRNA expression was measurably lower in TC/CC carriers than in TT homozygotes (p=0.043). This is the same functional gradient — TT > TC > CC in MTOR expression — seen with the rs2295080 promoter variant, achieved through a completely different molecular lever.

The Evidence

Cancer prognosis: The most functionally informative study examined 1,002 Chinese gastric cancer patients. The rs2536 C allele was independently associated with a 26% reduction in death risk³³ The rs2536 C allele was independently associated with a 26% reduction in death risk
Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. Int J Cancer, 2019 (HR 0.74, 95% CI 0.57–0.96, p=0.022). This survival benefit persisted after adjusting for tumor stage, age, and treatment. Functional follow-up showed that lower mTOR expression in TC/CC carriers correlated with reduced cancer cell proliferation, migration, and invasion in vitro.

Cancer susceptibility: Results are mixed and cancer-type-dependent. In a prostate cancer study of 1,004 Eastern Chinese cases and 1,051 controls, TC/CC genotypes were associated with increased prostate cancer risk⁴⁴ TC/CC genotypes were associated with increased prostate cancer risk
Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population. PLOS One, 2013 (dominant model OR 1.42, 95% CI 1.13–1.78, p=0.003). In childhood acute lymphoblastic leukemia, the direction reversed: the TC genotype was associated with a significantly decreased leukemia risk (adjusted OR 0.67, 95% CI 0.46–0.96), with stronger protection in T-phenotype ALL (OR 0.29 for TC/CC combined). The opposing directions by cancer type mirror the same paradox seen with rs2295080 and leukemia — mTOR biology in hematological malignancies appears distinct from solid tumors.

Meta-analysis: A comprehensive pooled analysis of 18 Chinese studies (6,653 cases, 7,025 controls) found no significant overall association across all cancer types, but within the population-based control subgroup (3,252 cases, 3,368 controls), rs2536 showed a significant association in the dominant model (OR 1.20, 95% CI 1.01–1.42, p=0.038) and allele model (OR 1.17, 95% CI 1.04–1.32, p=0.012). The overall null result reflects heterogeneity across cancer types rather than true absence of effect.

The evidence base is almost entirely from Chinese populations. European and other ancestry data are sparse, warranting the moderate evidence rating.

Practical Actions

The actionable implications of rs2536 overlap substantially with those of rs2295080, since both variants regulate mTOR expression in the same direction. TT homozygotes have the highest mTOR expression of the three genotypes and benefit most from deliberate behavioral mTOR suppression: extended overnight fasting, periodic protein restriction, and regular endurance exercise (which activates AMPK, the natural antagonist of mTOR). TC carriers have intermediate mTOR activity and similar but lower-urgency considerations. CC carriers have the lowest mTOR expression and enjoy the most favorable cancer prognosis signal, though they may need to be deliberate about maintaining adequate protein intake to support muscle mass, since mTOR also drives anabolic signaling.

Regardless of genotype, mTOR activity is suppressed by: fasting (the most potent lever), leucine restriction, and exercise-induced AMPK activation. It is stimulated by: dietary protein (especially whey and BCAAs), insulin, and IGF-1. The rs2536 genotype tells you how aggressively you need to apply these tools given your constitutive mTOR expression level.

Interactions

rs2536 and rs2295080 are independent MTOR variants that regulate mTOR expression through different mechanisms (3'UTR miRNA binding vs. promoter transcription factor binding). Carriers of the protective allele at both sites (rs2536 C and rs2295080 G) would be expected to have the lowest overall MTOR expression. Neither variant has been studied in combination in a single cohort, but the additive biology is straightforward — both attenuate the same protein.

The broader PI3K-AKT-mTOR signaling axis involves upstream variants in PTEN, AKT1, and TSC1/TSC2 that modulate how strongly growth signals activate mTOR. Downstream, FOXO3 (rs2802292) operates in the same longevity network: AKT phosphorylates and inactivates FOXO3, so lower mTOR activity in rs2536 C carriers means less AKT-driven FOXO3 suppression, complementing the longevity biology of the FOXO3 G-allele.

The ACVRL1 gene encodes ALK1¹¹ ALK1
Activin receptor-like kinase 1, also written ACVRL1 — a serine/threonine kinase receptor expressed predominantly on vascular endothelial cells throughout the body, a receptor that sits on the surface of blood vessel lining cells and binds the growth factors BMP9 and BMP10²² BMP9 and BMP10
Bone morphogenetic proteins 9 and 10 — despite their names, these proteins are key regulators of vascular development and stability, not just bone growth. When ALK1 is working normally, this BMP9/BMP10 signaling keeps blood vessel walls stable and prevents aberrant vessel sprouting. When one copy of ACVRL1 carries a pathogenic variant like Gly211Asp, vascular stability breaks down — small arteriovenous connections form and enlarge into arteriovenous malformations³³ arteriovenous malformations
AVMs — direct artery-to-vein connections that bypass the capillary bed. Blood under arterial pressure floods directly into veins, causing rupture, shunting, and downstream organ damage in the nose, skin, lungs, liver, and brain.

This condition is called hereditary hemorrhagic telangiectasia type 2⁴⁴ hereditary hemorrhagic telangiectasia type 2
HHT2, also known as Rendu-Osler-Weber syndrome — a rare autosomal dominant vascular disorder affecting approximately 1 in 5,000 people worldwide. A single pathogenic ACVRL1 allele is sufficient to cause HHT2, and nearly all carriers will develop some disease manifestation over a lifetime, though severity varies considerably even within the same family.

The Mechanism

Gly211 sits within the kinase domain of ALK1, the enzymatic core that phosphorylates downstream signaling proteins (SMAD1/5/8) when BMP9 or BMP10 binds. Glycine's small, flexible structure at this conserved position is essential for maintaining the correct geometry of the kinase active site. Replacing glycine with the larger, charged aspartic acid (p.Gly211Asp, c.631G>A) disrupts the catalytic pocket, impairing or abolishing kinase activity. The result is a loss-of-function allele⁵⁵ loss-of-function allele
haploinsufficiency — having 50% of normal ALK1 signaling is insufficient to maintain normal vascular endothelial quiescence. ACVRL1 pathogenic missense variants are concentrated at highly conserved residues; Gly211 shows strong evolutionary conservation, consistent with essential structural function.

Without adequate ALK1 signaling, endothelial cells over-proliferate and fail to suppress angiogenic sprouting, creating the direct artery-to-vein connections characteristic of HHT.

The Evidence

The French-Italian HHT network study⁶⁶ French-Italian HHT network study
Lesca et al., Genet Med, 2007 — multicenter genotype-phenotype analysis comparing 239 HHT1 (ENG) and HHT2 (ACVRL1) patients established key clinical distinctions between HHT subtypes. HHT2 (ACVRL1) shows symptomatic pulmonary AVMs in 5.2% of patients (vs 34.4% in HHT1), but hepatic AVM involvement is found almost exclusively in HHT2, and gastrointestinal bleeding is more frequent (16.4% vs 6.5%). Cerebral abscess from paradoxical embolism through pulmonary AVMs occurred in 0.8% of HHT2 vs 7.5% of HHT1 patients.

The Second International HHT Guidelines⁷⁷ Second International HHT Guidelines
Faughnan et al., Ann Intern Med, 2020 — 36 recommendations from 42 international experts covering screening, bleeding management, pregnancy, and pediatric care recommend systematic vascular screening for all HHT gene carriers, starting in childhood. Antifibrinolytics (tranexamic acid) and antiangiogenic therapy (bevacizumab) are now guideline-recommended for bleeding management. A randomized phase 2 trial⁸⁸ randomized phase 2 trial
Dupuis-Girod et al., J Intern Med, 2023 — 24 patients, bevacizumab vs placebo; hemoglobin significantly improved at 6 months in bevacizumab group (p=0.02) supports IV bevacizumab for severe HHT-related anemia.

ClinVar classifies the G>A allele (Gly211Asp) as Pathogenic/Likely Pathogenic for both HHT2 and pulmonary arterial hypertension related to HHT (variation ID 23292).

Practical Actions

Carriers of this variant require proactive surveillance. Pulmonary AVMs warrant transthoracic contrast echocardiography (bubble echo) every 3–5 years; even in HHT2, where pulmonary AVMs are less frequent than HHT1, the risk of paradoxical stroke or cerebral abscess from shunting is real. Brain MRI is recommended during childhood and again by age 18–20 to screen for cerebral AVMs. Adults need hepatic imaging to detect liver AVMs, which are more prevalent in HHT2. Recurrent epistaxis — often the earliest symptom, typically beginning in the second decade of life — should prompt iron studies and supplementation ahead of symptomatic anemia.

Interactions

ACVRL1 loss-of-function mutations interact biologically with the ENG (endoglin) and SMAD4 pathways, which operate in the same BMP signaling cascade. Concurrent pathogenic variants in SMAD4 (rs387907257 and related) cause a combined HHT-juvenile polyposis syndrome requiring additional gastrointestinal cancer surveillance beyond standard HHT management. Carriers of ACVRL1 pathogenic variants who also develop pulmonary arterial hypertension (a recognized complication) may need BMPR2 pathway evaluation, as ACVRL1 and BMPR2 share signaling converging on SMAD1/5/8.

The LDL receptor (LDLR)¹¹ LDL receptor (LDLR)
The LDLR gene encodes a cell-surface receptor that removes LDL particles from the bloodstream by binding them and pulling them into the cell for processing is the primary gatekeeper of blood cholesterol. Every cell that needs cholesterol displays LDLR on its surface; the liver uses it most heavily to clear LDL from circulation. When LDLR is absent or non-functional, LDL-C accumulates — a condition called familial hypercholesterolemia (FH).

The Y828C variant (rs28942085) is the historically important "J.D. mutation" — one of the first LDLR variants to be fully characterized at the protein level. It is caused by an A→G change at codon 828, substituting tyrosine with cysteine (p.Tyr828Cys). A second alternate allele (A→C, p.Tyr828Ser) also exists at this position and is classified as likely pathogenic.

The Mechanism

Normal LDLR internalization depends on a tyrosine-based coated-pit targeting signal²² coated-pit targeting signal
Coated pits are specialized regions of the plasma membrane coated with clathrin protein that pinch off to form endosomes, carrying receptor-bound cargo into the cell in the cytoplasmic tail of the receptor. In 1986, Davis et al.³³ Davis et al.
Davis CG et al. The J.D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell, 1986 showed that the Y828C substitution at residue 807 of the mature protein (now numbered 828 in the full pre-protein sequence) destroys this signal. The mutant receptor binds LDL normally but is distributed diffusely across the cell surface instead of concentrating in coated pits. It cannot be efficiently endocytosed, so LDL remains in the bloodstream.

The result is a receptor that is present but functionally paralysed at the final step of lipid uptake. Heterozygous carriers produce one defective receptor copy and one normal copy, giving roughly 50% of normal LDLR activity — enough to cause persistent LDL-C elevation. Homozygous carriers have near-complete loss of LDLR function.

The Evidence

This specific variant has been classified as Pathogenic/Likely pathogenic by five independent submitters in ClinVar (VCV000003893, 2-star review status), including functional studies in fibroblasts and CHO cells from the University of São Paulo and clinical testing data from Revvity Omics.

At the disease level, the clinical burden of FH is well established. Henderson et al. 2016⁴⁴ Henderson et al. 2016
Henderson et al. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci, 2016 confirmed that FH affects approximately 1 in 250 people globally, though the majority remain undiagnosed. Heterozygous FH produces LDL-C typically >190 mg/dL (untreated mean ~243 mg/dL in clinical cohorts), while homozygous FH drives LDL-C above 500 mg/dL with cardiovascular events in childhood.

Long-term cardiovascular risk data from Kjærgaard et al. 2017⁵⁵ Kjærgaard et al. 2017
Kjærgaard et al. Long-term cardiovascular risk in heterozygous familial hypercholesterolemia relatives identified by cascade screening. J Am Heart Assoc, 2017 following 220 relatives from cascade screening for over 20 years found that LDLR mutation carriers had a hazard ratio of 1.94 (95% CI 1.14–3.31) for major cardiovascular events compared with non-carrying relatives — even though 89% of carriers were taking statins throughout follow-up.

Practical Actions

Heterozygous FH is highly treatable. High-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) reduce LDL-C by 50–55%; most heterozygous carriers can reach guideline targets with a statin plus ezetimibe. Carriers who cannot achieve adequate LDL-C reduction with maximal-dose statins and ezetimibe are candidates for PCSK9 inhibitors (evolocumab, alirocumab), which reduce LDL-C by a further 50–60% on top of statin therapy.

Saturated fat restriction (below 7% of total calories) and avoidance of trans fats complement medical therapy but cannot substitute for it — dietary changes alone produce only modest reductions (typically 10–20% at most) in LDL-C when the underlying receptor defect remains.

Cascade screening — testing all first- and second-degree relatives of a confirmed carrier — is the most cost-effective strategy for identifying undiagnosed FH and is recommended by all major cardiology guidelines.

Interactions

FH severity is modulated by other lipid-pathway variants. Concurrent APOE4 (rs429358) worsens LDL-C elevation because APOE4 particles are cleared less efficiently even through intact receptors. APOB pathogenic variants (e.g. rs5742904, familial defective ApoB) cause a clinically similar phenotype and should be excluded when LDLR sequencing is negative. Carriers of two LDLR pathogenic alleles (homozygous FH) or compound heterozygotes with one LDLR and one APOB pathogenic allele present with much more severe disease (LDL-C

400–500 mg/dL) and require LDL apheresis in addition to maximal pharmacotherapy.

Every amino acid your body breaks down for energy releases nitrogen in the form of ammonia — a molecule that is toxic to the brain even at low concentrations. The urea cycle¹¹ urea cycle
A five-enzyme sequence in liver cells that converts ammonia to urea, which is then excreted in urine; collectively handles ~90% of the body's waste nitrogen exists to neutralize this steady stream of ammonia before it reaches the bloodstream. Argininosuccinate lyase (ASL) performs the fourth step: cleaving argininosuccinate into arginine and fumarate. When this step fails, argininosuccinate accumulates in blood and urine, the cycle backs up, and ammonia rises. ASL deficiency (argininosuccinic aciduria, or ASA) is the second most common urea cycle disorder, estimated at ~1 in 70,000 live births globally²² second most common urea cycle disorder, estimated at ~1 in 70,000 live births globally.

The Q354X variant (c.1060C>T in the canonical transcript; classified as a stop-gained variant at GRCh38 chr7:66089693³³ stop-gained variant at GRCh38 chr7:66089693) introduces a premature stop codon at position 354 of the 464-amino-acid ASL protein. The truncated protein is non-functional: the C-terminal region it loses contains critical residues for the enzyme's tetrameric assembly and catalytic activity. Q354X is listed as Pathogenic in ClinVar (VCV000021253)⁴⁴ Pathogenic in ClinVar (VCV000021253) with multiple submitters and no conflicts.

The Mechanism

ASL catalyzes the reversible elimination of fumarate from argininosuccinate, yielding arginine. In its normal form, the enzyme assembles as a homotetramer, and the active sites sit at subunit interfaces — a structural arrangement that makes even partial loss of functional subunits disproportionately disruptive. The Q354X truncation eliminates the C-terminal segment entirely, preventing correct folding and tetramer formation. The result is a complete loss of enzymatic activity from the Q354X allele.

Beyond the urea cycle bottleneck, ASL has a second metabolic role that explains some of its most distinctive clinical features. Nagamani et al. 2012 (AJHG)⁵⁵ Nagamani et al. 2012 (AJHG)
Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. Am J Hum Genet 2012;90:836-46 demonstrated that ASL is required not just for urea synthesis but for channeling arginine to nitric oxide synthase (NOS) for nitric oxide production. Without functional ASL, nitric oxide (NO)⁶⁶ nitric oxide (NO)
The endothelial signaling molecule essential for blood vessel relaxation and blood pressure regulation; produced when NOS converts arginine to citrulline synthesis is impaired even when plasma arginine levels appear adequate. This NO deficiency causes systemic hypertension that can be refractory to conventional antihypertensives — a complication specific to ASL deficiency and largely absent in other urea cycle disorders where ASL is intact.

The Evidence

Q354X was characterized as a Saudi founder mutation by Al-Sayed et al. 2005⁷⁷ Al-Sayed et al. 2005
Identification of a common novel mutation in Saudi patients with argininosuccinic aciduria. J Inherit Metab Dis 2005, who found the allele in 14 of 28 Saudi ASA patients — representing approximately 50% of abnormal ASL alleles in their cohort. The authors recommended routine testing for Q354X and Q116X in all ASA patients of Arab origin. This high allele frequency in Saudi patients, combined with near-absence in non-Arab populations (no observed instances in large European, East Asian, or African cohorts in gnomAD), confirms its founder mutation status.

The largest Saudi clinical series, AlTassan et al. 2018⁸⁸ AlTassan et al. 2018
European Journal of Medical Genetics, n=54 patients, confirmed Q354X as the dominant variant. Q354X homozygotes had a higher frequency of hyperammonemia episodes than patients with other mutations. Despite 92% receiving early diagnosis (before 28 days through newborn screening), 90.7% developed developmental delay and 62.9% had seizure disorders by the time of review (mean age 10 years), illustrating that ammonia control during neonatal crises is necessary but not sufficient to prevent long-term neurocognitive damage. Thrombocytosis was unexpectedly prevalent (96%), a finding without clear mechanistic explanation.

A long-term Austrian cohort study (n=17, median age 13 years) Mercimek-Mahmutoglu et al. 2010⁹⁹ Mercimek-Mahmutoglu et al. 2010
Mol Genet Metab 2010 documented more favorable outcomes in newborn-screened patients, with 65% achieving average or above-average IQ — an important benchmark for what aggressive early management can achieve. However, three patients still developed hepatic steatosis, underscoring that liver complications emerge independent of ammonia control.

A key finding across studies: there is no correlation between genotype, enzyme activity, and clinical outcome¹⁰¹⁰ no correlation between genotype, enzyme activity, and clinical outcome in ASL deficiency. Q354X homozygosity cannot predict clinical severity in an individual, which is why ongoing monitoring rather than genotype-alone decision-making guides management.

Practical Actions

ASL deficiency is diagnosed in the neonatal period through newborn screening via elevated citrulline and argininosuccinic acid on tandem mass spectrometry. Affected individuals presenting for the first time through a genome report are almost certainly already under specialist metabolic care. The management summary below reflects established clinical practice:

Unlike most other urea cycle disorders, ASL deficiency requires arginine supplementation rather than restriction — because the urea cycle stalls before arginine is produced, affected individuals cannot synthesize adequate arginine endogenously and must receive exogenous free-base arginine to meet cellular needs while simultaneously providing a substrate cycle that allows some residual nitrogen clearance.

Long-term complications extend beyond ammonia: hepatic fibrosis, steatosis, and systemic hypertension all occur at higher rates than in the general population and require dedicated monitoring independent of plasma ammonia levels.

Interactions

Within the ASL gene, compound heterozygosity — carrying Q354X on one chromosome and a different pathogenic ASL allele on the other — produces clinical ASL deficiency identical to Q354X homozygosity. The Al-Sayed 2005 study documented compound Q354X/Q116X cases in Saudi patients. All compound heterozygous combinations of two null alleles carry the same management requirements.

The Q354X lesion sits at the fourth step of the urea cycle, which depends on substrate delivery from the three preceding steps (CPS1, OTC, ASS1). Variants in those upstream enzymes do not compound the severity of Q354X deficiency — the Q354X block is itself complete and rate-limiting. Downstream, the loss of arginine production impairs the nitric oxide synthase pathway (eNOS, nNOS), producing secondary NO deficiency-mediated cardiovascular and neurological effects that are specific to ASL among urea cycle disorders.

Your arteries are constantly remodeling. Smooth muscle cells, collagen fibers, and immune cells weave together to form atherosclerotic plaques — and whether those plaques stay stable or rupture depends heavily on the enzymes that digest the extracellular matrix. MMP-9 (matrix metalloproteinase 9) is one of the most destructive of these enzymes in the vascular wall. The rs3918242 C-1562T variant sits in the MMP9 promoter and controls how much of this enzyme your vascular cells produce.

The Mechanism

The C-to-T substitution at position −1562 in the MMP9 promoter disrupts an SP1 transcription factor binding site¹¹ disrupts an SP1 transcription factor binding site
SP1 (specificity protein 1) is a zinc-finger transcription factor that normally suppresses MMP9 transcription when bound at this position. When the T allele is present, SP1 binding affinity is reduced, releasing the brakes on MMP9 expression. The result: higher baseline and inducible MMP-9 levels in vascular smooth muscle cells, macrophages, and endothelial cells.

MMP-9 is a gelatinase (also called gelatinase B) that digests type IV and V collagen, gelatin, and fibronectin — the structural scaffold of the fibrous cap that keeps atherosclerotic plaques stable. Elevated MMP-9 thins and weakens the fibrous cap, increasing the likelihood of sudden rupture. Plaque rupture is the proximate cause of most acute myocardial infarctions and many ischemic strokes. The gene sits on chromosome 20q11.21–13.12, and all alleles at this locus are reported on the plus (forward) strand, so C is the reference protective allele and T is the risk allele.

The Evidence

The largest meta-analysis, by Hassanzadeh-Makoui et al. (BMC Cardiovascular Disorders, 2020)²² Hassanzadeh-Makoui et al. (BMC Cardiovascular Disorders, 2020)
40 studies, 11,792 CAD cases and 8,280 controls, found the T allele conferred significant CAD risk under every genetic model: dominant OR 1.41, recessive OR 1.59, and TT vs. CC OR 1.70 (all P < 0.001). The effect was driven by Asian populations, with no significant association in Europeans.

An updated analysis by Zhang et al. (Oncotarget, 2017)³³ Zhang et al. (Oncotarget, 2017)
37 studies, 24,407 total participants confirmed this pattern: overall CAD OR 1.34 (95% CI 1.20–1.50), rising to OR 1.66 for MI in Asian populations under the allelic model (OR 2.29 recessive). The modest effect in Europeans does not negate the biological plausibility — MMP-9 expression differences have been demonstrated in human coronary tissue regardless of ethnicity.

For stroke, a separate meta-analysis by Wang et al. (Journal of Cellular Biochemistry, 2018)⁴⁴ Wang et al. (Journal of Cellular Biochemistry, 2018)
16 studies, 7,332 participants found the T allele increased stroke risk, particularly ischemic stroke in Asian populations.

In patients with type 2 diabetes, the risk is amplified: a study by Buraczynska et al. (Journal of Clinical Medicine, 2023)⁵⁵ Buraczynska et al. (Journal of Clinical Medicine, 2023)
1,140 participants found CT/TT genotypes associated with CVD risk OR 2.87 for the T allele and OR 3.19 for TT homozygotes, with reduced HDL as a correlated finding.

Practical Actions

T allele carriers benefit from strategies that target MMP-9-driven plaque biology specifically: dietary approaches that reduce MMP-9 induction, monitoring that catches subclinical atherosclerosis early, and awareness of drug interactions that may modulate MMP-9 activity. Statins have documented MMP-9-suppressing effects at the transcriptional level — an additional reason for lipid management decisions in T allele carriers.

Interactions

The rs3918242 C-1562T variant interacts with the rs17576 (MMP9 Q279R) missense variant in the same gene. Studies have examined combined carriership of both polymorphisms in relation to coronary artery disease and plaque remodeling. Carriers of risk alleles at both positions may experience additive effects on MMP-9 activity — elevated expression from the promoter variant combined with altered substrate specificity from the coding variant. Interaction with rs2250889 (MMP9 R668Q) has also been reported in cardiovascular contexts. The supervisor agent should evaluate compound actions for co-carriership of rs3918242 T and rs17576 A alleles.

Every time a biotin-dependent enzyme finishes its job — carboxylating pyruvate, acetyl-CoA, propionyl-CoA, or 3-methylcrotonyl-CoA — the biotin cofactor is covalently attached to the enzyme and must be liberated before it can be reused. Biotinidase¹¹ Biotinidase
Encoded by the BTD gene on chromosome 3p25; a serum enzyme that cleaves biocytin (biotinyl-lysine) to free biotin for re-use across the four biotin-dependent carboxylases that drive fat, protein, and carbohydrate metabolism is the enzyme responsible for this recycling step. When both copies of BTD are non-functional, free biotin becomes depleted, all four carboxylases fail, and a characteristic neurocutaneous syndrome²² neurocutaneous syndrome
Biotinidase deficiency (OMIM #253260): autosomal recessive disorder presenting with seizures, hypotonia, ataxia, dermatitis, alopecia, and sensorineural hearing loss — reversible with biotin supplementation if treated early follows within weeks to years.

The rs397507174 variant (c.569A>G on the BTD coding sequence, plus strand) replaces tyrosine at position 190 of the biotinidase protein with cysteine (p.Tyr190Cys). The substitution introduces a free thiol group at a position that normally anchors a bulkier aromatic residue within the carbon-nitrogen hydrolase domain³³ carbon-nitrogen hydrolase domain
The catalytic core of biotinidase; contains the active-site cysteine nucleophile (Cys153) that attacks the amide bond of biocytin. Tyr190 is a conserved residue in the substrate-binding pocket adjacent to this active site. ClinVar classifies this variant as Pathogenic/Likely Pathogenic (VCV000046830, two-star review status, no conflicting interpretations) for biotinidase deficiency.

The Mechanism

Biotinidase catalyses the hydrolysis of biocytin through a two-step mechanism: a nucleophilic attack by the active-site Cys153 forms a biotinyl-enzyme intermediate, followed by transfer of biotin to an acceptor (free amino group or water). Conserved residues in the substrate-binding pocket position biocytin for this reaction. Tyr190 is predicted to contribute to substrate orientation — its replacement with cysteine alters the geometry of the binding pocket and impairs catalytic turnover. Bioinformatic tools (SIFT, PolyPhen) flag this substitution as damaging; the position is conserved across vertebrate biotinidase orthologues.

When biotinidase activity falls to less than 10% of mean normal serum activity, free biotin cannot be recovered efficiently from biocytin generated by protein turnover and dietary intake. The biotin pool depletes, and all four biotin- dependent carboxylases — pyruvate carboxylase (gluconeogenesis)⁴⁴ pyruvate carboxylase (gluconeogenesis)
PC deficiency causes lactic acidosis and hypoglycaemia, acetyl-CoA carboxylase (fatty acid synthesis)⁵⁵ acetyl-CoA carboxylase (fatty acid synthesis)
ACC1/ACC2 deficiency impairs fatty acid synthesis and beta-oxidation regulation, propionyl-CoA carboxylase (odd-chain fatty acid and amino acid catabolism)⁶⁶ propionyl-CoA carboxylase (odd-chain fatty acid and amino acid catabolism)
PCC deficiency causes propionate accumulation and metabolic acidosis, and 3-methylcrotonyl-CoA carboxylase (leucine catabolism) — lose function in concert, producing the organic aciduria and metabolic crisis characteristic of profound biotinidase deficiency.

The Evidence

The defining clinical study is Pomponio et al. (1997)⁷⁷ Pomponio et al. (1997)
Pomponio RJ et al. Mutations in the human biotinidase gene that cause profound biotinidase deficiency in symptomatic children: molecular, biochemical, and clinical analysis. Pediatr Res, 1997, which characterized 21 distinct BTD mutations in 37 symptomatic children with profound deficiency. The Tyr190Cys variant (rs397507174) was among the mutations submitted to ClinVar from this and related studies, and is classified pathogenic by Baylor Genetics, LabCorp, and Counsyl in the ClinVar record (RCV000021949).

The broader disease framework is well established: Wolf (2012)⁸⁸ Wolf (2012)
Wolf B. Biotinidase deficiency: "if you have to have an inherited metabolic disease, this is the one to have." Genet Med, 2012 reviewed the >150 BTD mutations known at that time, all of which produce profound deficiency (<10% activity) except D444H, which retains ~50% activity and causes partial deficiency. Tyr190Cys falls into the profound-deficiency category based on its predicted complete disruption of the substrate-binding pocket.

Newborn screening using a colorimetric biotinidase activity assay on dried blood spots has been universal in the United States since 1984 and is now standard in most countries. Norrgard et al. (1999)⁹⁹ Norrgard et al. (1999)
Norrgard KJ et al. Mutations causing profound biotinidase deficiency in children ascertained by newborn screening in the United States occur at different frequencies than in symptomatic children. Pediatr Res, 1999 showed that newborn-detected children have better outcomes than symptom-detected children, confirming the benefit of early treatment. Untreated profound deficiency causes seizures, hypotonia, developmental delay, sensorineural hearing loss (in ~76% of untreated patients), optic atrophy, and eventually coma or death. With timely biotin supplementation, all metabolic abnormalities reverse rapidly and development is typically normal.

Practical Actions

For carriers (one copy of Tyr190Cys): biotinidase activity is reduced to an intermediate level (typically 30–65% of normal) but this is sufficient for normal biotin homeostasis under most conditions. Carriers do not develop biotinidase deficiency. The primary relevance is reproductive: if both partners carry a pathogenic BTD variant, each pregnancy has a 25% chance of a child with profound deficiency. Carrier couple screening is indicated.

For individuals with biallelic Tyr190Cys, or compound heterozygotes (one Tyr190Cys allele plus any other pathogenic BTD allele): this is a medical diagnosis. The treatment is pharmacological free biotin by mouth — 5–10 mg/day for profound deficiency — which completely bypasses the recycling defect by providing exogenous free biotin directly. Clinical response is rapid: seizures resolve within days to weeks, cutaneous features within weeks, and metabolic parameters normalise. Neurological deficits (hearing loss, optic atrophy) may not fully reverse once established, underscoring the importance of early detection and treatment.

Interactions

Biotinidase deficiency requires biallelic loss of BTD function. Compound heterozygosity — one Tyr190Cys allele on one chromosome plus any other pathogenic BTD variant on the other — produces the same clinical picture as homozygous Tyr190Cys. The most common pathogenic BTD allele globally is D444H (c.1330G>C, p.Asp444His, rs13078881), which causes only partial deficiency when homozygous but can cause profound deficiency when combined with a severe allele like Tyr190Cys. Carriers of Tyr190Cys who have a partner of similar ancestry should consider BTD sequencing of the partner to assess compound-heterozygote risk for offspring.

Cilia are microscopic hair-like projections that line virtually every airway in your respiratory tract, propelling mucus and trapped particles upward and out of your lungs. The engine that drives ciliary beating is the outer dynein arm¹¹ outer dynein arm
a multi-protein motor complex attached to the outer doublet microtubules of the ciliary axoneme; it converts ATP into the mechanical force that drives ciliary movement — and DNAI1 encodes one of its essential structural components (the intermediate chain IC78/DNAI1). When both copies of DNAI1 are non-functional, cilia stop beating normally, mucus accumulates in the airways, and the condition known as primary ciliary dyskinesia (PCD) results.

rs397515563 (also written IVS19+1G>A or c.2001+1G>A) disrupts the canonical splice donor GT dinucleotide²² canonical splice donor GT dinucleotide
the invariant GT at the +1 position of an intron splice donor site is required for the spliceosome to recognize and excise the intron; changing it abolishes normal splicing at the start of intron 19. The result is that exon 19 is skipped entirely during mRNA processing, producing a protein with 61 amino acids deleted (A607_K667del). This deleted region falls within a functional domain of the outer dynein arm intermediate chain, and the truncated protein cannot support normal ciliary structure.

The Mechanism

DNAI1 (dynein axonemal intermediate chain 1) is a 699-amino-acid protein that forms part of the outer dynein arm (ODA) — the molecular motor unit attached at regular intervals along the outer doublet microtubules of the ciliary axoneme. The ODA generates the sliding force between microtubule doublets that produces ciliary beating. When either ODA motor protein subunit is absent or non-functional, cilia either cannot beat or beat in abnormal, uncoordinated patterns that fail to generate net airway flow.

The IVS19+1G>A substitution changes the invariant G at position +1 of intron 19 to an A. This single nucleotide change abolishes the canonical GT splice donor sequence recognized by the U1 snRNA component of the spliceosome. In vitro splicing assays confirmed³³ In vitro splicing assays confirmed
performed by Zariwala et al. using patient cDNA and minigene constructs; the assay directly demonstrated exon 19 skipping in the presence of the IVS19+1G>A mutation that the mutant allele produces a shortened mRNA lacking exon 19, which is translated into a DNAI1 protein missing residues A607 through K667. The resulting protein cannot properly integrate into outer dynein arm complexes.

Because PCD is autosomal recessive, one functional DNAI1 copy is sufficient for normal ciliary structure and function. Carriers of a single IVS19+1G>A allele paired with a normal allele produce enough wild-type DNAI1 protein from their unaffected chromosome and have completely normal mucociliary clearance with no respiratory symptoms attributable to this variant.

The Evidence

Zariwala et al. 2006⁴⁴ Zariwala et al. 2006
American Journal of Respiratory and Critical Care Medicine; 179 unrelated PCD families identified the IVS19+1G>A mutation in a patient with PCD who carried it in trans with the founder IVS1+2_3insT mutation. The study found DNAI1 mutations in 9% of families overall and confirmed via in vitro splicing assay that IVS19+1G>A produces exon 19 skipping and the in-frame deletion of 61 amino acids (A607_K667del). When considering only families with outer dynein arm (ODA) defects on electron microscopy — the ultrastructural hallmark of DNAI1 mutations — the frequency rises to 13–14%.

Guichard et al. 2001⁵⁵ Guichard et al. 2001
American Journal of Human Genetics; 34 PCD patients established that compound heterozygosity in DNAI1 produces both Kartagener syndrome (PCD with situs inversus) and PCD without organ reversal. The randomization of left-right body asymmetry in PCD occurs because embryonic nodal cilia — the left-right organizer — depend on the same dynein arm machinery; ODA defects disrupt directional nodal flow, leading to ~50% chance of situs inversus.

Ziétkiewicz et al. 2010⁶⁶ Ziétkiewicz et al. 2010
Respiratory Research; 157 Polish PCD families examined population specificity of DNAI1 mutations and confirmed that DNAI1 accounts for 7–10% of worldwide PCD, with the IVS1+2-3insT founder mutation comprising ~54% of all identified DNAI1 pathogenic alleles globally. The IVS19+1G>A variant is one of the rarer DNAI1 mutations, observed at an allele frequency of approximately 0.000002 in gnomAD exomes.

For disease management, PCD Foundation consensus recommendations⁷⁷ PCD Foundation consensus recommendations
Shapiro et al. 2016; expert panel covering airway clearance, surveillance culture protocols, antibiotic regimens, ENT care, and fertility provide the current clinical standard of care. An emerging therapeutic approach — inhaled DNAI1 mRNA lipid nanoparticle therapy⁸⁸ inhaled DNAI1 mRNA lipid nanoparticle therapy
Hennig et al. 2025 (PNAS); preclinical study demonstrating protein production in NHP airways and functional rescue in PCD cell models at therapeutic doses — has shown preclinical promise for gene-specific restoration of ciliary function.

Practical Implications

Carriers (one IVS19+1G>A allele, one normal allele) are completely unaffected. No respiratory symptoms, no hearing issues, no laterality defects. The only practical relevance for a carrier is reproductive: if both partners in a couple carry pathogenic DNAI1 variants (on different alleles), each pregnancy carries a 25% risk of producing an affected child with PCD. Genetic counseling and partner testing are the key actions.

For affected individuals with PCD (biallelic DNAI1 mutations): management is coordinated through respiratory medicine, ENT, audiology, and (for males) andrology. Airway clearance therapy is the cornerstone. Nearly 100% of males with PCD are infertile due to sperm flagellar immotility from the same ODA defect — but assisted reproductive techniques, particularly ICSI, achieve successful fertilization because sperm vitality (DNA integrity) is preserved even when motility is absent.

Interactions

PCD is genetically heterogeneous — over 50 genes encoding axonemal components can cause the condition when both copies are disrupted. The most common DNAI1 pathogenic allele (IVS1+2-3insT, the founder mutation accounting for ~54% of DNAI1 alleles worldwide) can pair with IVS19+1G>A in compound heterozygosity to produce full PCD. DNAH5 (outer dynein arm heavy chain) and DNAAF1 (dynein axonemal assembly factor 1) are among the other ODA genes; loss-of-function variants in any of these can combine with DNAI1 variants only within the same gene (compound heterozygosity within DNAI1 is required for disease — heterozygosity for DNAI1 + DNAH5 does not produce PCD because different subunits complement each other).

Every heartbeat depends on a choreography of proteins that contract precisely and relax completely. At the heart of this machinery sits cardiac myosin-binding protein C (cMyBP-C)¹¹ cardiac myosin-binding protein C (cMyBP-C)
encoded by MYBPC3, this 1,274 amino acid protein acts as both a structural scaffold of the cardiac thick filament and a regulatory brake on myosin-actin interaction; it is phosphorylated by PKA during exercise to allow the heart to increase output, which integrates the myosin motor machinery into a regulated, ordered structure called the sarcomere. Pathogenic variants in MYBPC3 are the single most common identified genetic cause of hypertrophic cardiomyopathy (HCM)²² hypertrophic cardiomyopathy (HCM)
abnormal thickening of heart muscle, particularly the interventricular septum, impairing ventricular filling and increasing the risk of dangerous arrhythmias, accounting for 40–50% of all genetically solved HCM cases globally.

This variant falls within the C5 immunoglobulin-like domain of cMyBP-C — one of ten immunoglobulin (Ig-like) and fibronectin type-III repeat units that form the protein's modular scaffold. The C5 domain is structurally unusual: it carries a 28-amino acid cardiac-specific insertion loop³³ 28-amino acid cardiac-specific insertion loop
absent from the skeletal muscle paralogs, sMyBP-C and fMyBP-C; the cardiac-specific loop has been proposed to mediate unique interactions with titin and other thick-filament components during sarcomere assembly present only in the cardiac isoform. This loop and the surrounding C5 Ig fold mediate key protein-protein interactions — particularly with titin — that anchor cMyBP-C in the correct sarcomeric register. Missense variants in C5 that disrupt these interfaces impair sarcomere assembly and reduce functional cMyBP-C protein, triggering HCM.

The Mechanism

Unlike the majority of MYBPC3 pathogenic variants (approximately 91% of which are truncating frameshift, splice, or nonsense mutations), missense variants like this one in C5 produce full-length protein with a single amino acid substitution. However, functional studies of MYBPC3 missense variants demonstrate that the disease mechanism converges on the same endpoint: haploinsufficiency⁴⁴ haploinsufficiency
reduction of functional cMyBP-C protein to approximately half its normal level, which is insufficient to maintain proper sarcomere architecture and cross-bridge regulation.

Human myectomy data from confirmed MYBPC3 pathogenic variant carriers⁵⁵ Human myectomy data from confirmed MYBPC3 pathogenic variant carriers
Marston et al. 2009, Circulation Research — examined 37 myectomy samples including both truncating and missense MYBPC3 mutations demonstrated that full-length MyBP-C protein was reduced approximately 24% versus donor controls (p<0.0005), with no truncated peptides detected. This rules out a dominant-negative poison protein mechanism: the mutant protein is either unstable and degraded, or fails to incorporate into sarcomeres, leaving the sarcomere with half its normal cMyBP-C complement.

The consequence of reduced cMyBP-C is dysregulated myosin cross-bridge kinetics: unrestrained myosin motors fire more frequently and asynchronously during both systole and diastole. The heart compensates through concentric hypertrophy — thickening its walls — which initially maintains output but progressively stiffens the ventricle, impairs diastolic filling, and creates a substrate for dangerous arrhythmias.

The Evidence

Helms et al. 2020⁶⁶ Helms et al. 2020
Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes; n=1,316 MYBPC3 HCM patients from the Sarcomeric Human Cardiomyopathy Registry established that nontruncating (missense) MYBPC3 pathogenic variants cluster significantly in the C3, C6, and C10 domains (82% of missense variants, p<0.001), with C5 being adjacent to these hotspot regions. Clinical outcomes for missense variant carriers were comparable to truncating variant carriers — both groups experienced similar rates of the composite adverse outcome (sudden cardiac death, resuscitated arrest, ICD therapy, transplant, LVAD, severe heart failure, atrial fibrillation, and stroke). This demonstrates that a single missense in a critical domain like C5 is as clinically consequential as a complete loss-of-function truncation.

MYBPC3 HCM follows incomplete, age-dependent penetrance⁷⁷ incomplete, age-dependent penetrance
not all variant carriers develop detectable HCM during their lifetime; those who do often present late. A founder mutation cohort study found penetrance of approximately 39% in male carriers under 40, rising to 86% by age 60. Female carriers show lower early penetrance (~9% under 40) but nearly equivalent late penetrance (83% over 60). Genotype-positive, phenotype-negative carriers exhibit subtle ECG and biomarker differences from unaffected relatives even before left ventricular hypertrophy appears — underscoring the need for structured surveillance even in the apparently unaffected.

Aging further exacerbates the HCM phenotype⁸⁸ Aging further exacerbates the HCM phenotype
three pathogenic pathways — nonsense- mediated mRNA decay, aberrant splicing, and ubiquitin-proteasome degradation of unstable mutant protein — all contribute to progressive haploinsufficiency, and aging hallmarks such as mitochondrial dysfunction and proteostatic stress amplify these effects over the lifetime of a carrier, explaining why the phenotype often worsens with age even without a new genetic event.

Practical Actions

Identifying a MYBPC3 C5 domain pathogenic carrier changes clinical management in ways that directly affect long-term outcomes. The 2024 AHA/ACC HCM guidelines recommend formal cardiac evaluation for all genotype-positive individuals and structured surveillance for those who are phenotype-negative at baseline. Mavacamten — a cardiac myosin inhibitor approved in 2022 — directly counteracts the sarcomeric hypercontractility caused by cMyBP-C haploinsufficiency and is now guideline-directed first-line therapy for symptomatic obstructive HCM (LVOT gradient ≥30 mmHg).

Each biological child, sibling, and parent of a MYBPC3 C5 domain variant carrier has a 50% chance of inheriting the pathogenic allele. Cascade genetic testing followed by structured cardiac surveillance in positive relatives enables early phenotypic detection and intervention before irreversible remodeling occurs.

Interactions

MYBPC3 missense variants in C5 operate through haploinsufficiency — a single pathogenic copy reduces total cMyBP-C protein enough to cause disease. Compound heterozygosity (two pathogenic MYBPC3 variants in trans, one on each chromosome) is rare but associated with severe, often neonatal-onset cardiomyopathy because the total functional protein falls to near-zero levels.

Co-inheritance with pathogenic variants in other sarcomere genes — particularly MYH7 (beta-myosin heavy chain), TNNT2 (cardiac troponin T), and TPM1 (alpha-tropomyosin, e.g. rs104894502) — constitutes "double-positive" HCM, associated with earlier onset and more severe hypertrophy than single-gene HCM. No published studies have specifically quantified the combined risk for MYBPC3 C5 domain missense plus variants in these other genes, but current clinical guidelines recommend treating double-positive genotypes as high-risk for risk stratification purposes.